New Haven, Connecticut-based Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company targeting neurological diseases, has filed for an $100 million IPO, according to an SEC filing. Biohaven has applied to list the stock on the New York Stock Exchange under the ticker symbol “BHVN.” Morgan Stanley, Piper Jaffray and Barclays are the lead underwriters. Biohaven’s shareholders include Portage Biotech Inc, Vivo Capital and RA Capital.
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated attorneys Stephanie M. Chesney
Burns & Levinson announced today that well-known plaintiff employment litigator Beth R. Myers has joined the firm
BayCoast Bank is delighted to announce Nicole Almeida as Senior Vice President, Chief Diversity Officer (CDO)
BayCoast Bank is pleased to announce Robert Bergdoll of Attleboro, Massachusetts, as First Vice President Marketing Director
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
